Vistin Pharma ASA (VISTN) - Net Assets
Based on the latest financial reports, Vistin Pharma ASA (VISTN) has net assets worth Nkr350.31 Million NOK (≈ $36.86 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr453.56 Million ≈ $47.73 Million USD) and total liabilities (Nkr103.25 Million ≈ $10.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Vistin Pharma ASA's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr350.31 Million |
| % of Total Assets | 77.24% |
| Annual Growth Rate | 6.5% |
| 5-Year Change | 19.18% |
| 10-Year Change | N/A |
| Growth Volatility | 63.73 |
Vistin Pharma ASA - Net Assets Trend (2016–2025)
This chart illustrates how Vistin Pharma ASA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Vistin Pharma ASA worth.
Annual Net Assets for Vistin Pharma ASA (2016–2025)
The table below shows the annual net assets of Vistin Pharma ASA from 2016 to 2025. Also explore Vistin Pharma ASA equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr328.81 Million ≈ $34.60 Million |
+6.23% |
| 2024-12-31 | Nkr309.53 Million ≈ $32.57 Million |
-4.10% |
| 2023-12-31 | Nkr322.77 Million ≈ $33.96 Million |
+18.12% |
| 2022-12-31 | Nkr273.26 Million ≈ $28.76 Million |
-0.95% |
| 2021-12-31 | Nkr275.89 Million ≈ $29.03 Million |
+1.28% |
| 2020-12-31 | Nkr272.40 Million ≈ $28.66 Million |
-34.11% |
| 2019-12-31 | Nkr413.40 Million ≈ $43.50 Million |
+18.50% |
| 2018-12-31 | Nkr348.85 Million ≈ $36.71 Million |
+190.33% |
| 2017-12-31 | Nkr120.16 Million ≈ $12.64 Million |
-35.61% |
| 2016-12-31 | Nkr186.61 Million ≈ $19.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vistin Pharma ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 557.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Nkr210.60 Million | 64.05% |
| Other Components | Nkr118.21 Million | 35.95% |
| Total Equity | Nkr328.81 Million | 100.00% |
Vistin Pharma ASA Competitors by Market Cap
The table below lists competitors of Vistin Pharma ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yirendai Ltd
NYSE:YRD
|
$87.27 Million |
|
Townsquare Media Inc
NYSE:TSQ
|
$87.29 Million |
|
Katmerciler Arac Ustu Ekipman Sanayi ve Ticaret AS
IS:KATMR
|
$87.29 Million |
|
Concorde International Group Ltd Class A Ordinary Shares
NASDAQ:CIGL
|
$87.30 Million |
|
KUYA SILVER CORP.
F:6MR1
|
$87.24 Million |
|
IFB Agro Industries Limited
NSE:IFBAGRO
|
$87.23 Million |
|
Hasen-Immobilien AG
STU:ABHA
|
$87.20 Million |
|
Banco Santander Río S.A
BA:BRIO
|
$87.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vistin Pharma ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 309,529,000 to 328,814,000, a change of 19,285,000 (6.2%).
- Net income of 74,751,000 contributed positively to equity growth.
- Dividend payments of 55,431,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr74.75 Million | +22.73% |
| Dividends Paid | Nkr55.43 Million | -16.86% |
| Other Changes | Nkr-35.00K | -0.01% |
| Total Change | Nkr- | 6.23% |
Book Value vs Market Value Analysis
This analysis compares Vistin Pharma ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.52x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.71x to 2.52x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Nkr10.94 | Nkr18.70 | x |
| 2017-12-31 | Nkr6.89 | Nkr18.70 | x |
| 2018-12-31 | Nkr7.87 | Nkr18.70 | x |
| 2019-12-31 | Nkr9.32 | Nkr18.70 | x |
| 2020-12-31 | Nkr6.14 | Nkr18.70 | x |
| 2021-12-31 | Nkr6.22 | Nkr18.70 | x |
| 2022-12-31 | Nkr6.16 | Nkr18.70 | x |
| 2023-12-31 | Nkr7.28 | Nkr18.70 | x |
| 2024-12-31 | Nkr6.98 | Nkr18.70 | x |
| 2025-12-31 | Nkr7.41 | Nkr18.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vistin Pharma ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.73%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.53%
- • Asset Turnover: 1.03x
- • Equity Multiplier: 1.34x
- Recent ROE (22.73%) is above the historical average (8.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 6.92% | 7.58% | 0.61x | 1.50x | Nkr-5.74 Million |
| 2017 | 58.59% | 39.84% | 0.76x | 1.93x | Nkr58.38 Million |
| 2018 | -21.11% | -37.00% | 0.40x | 1.43x | Nkr-108.51 Million |
| 2019 | 16.01% | 29.14% | 0.45x | 1.22x | Nkr24.86 Million |
| 2020 | -35.59% | -38.30% | 0.79x | 1.18x | Nkr-124.20 Million |
| 2021 | 9.05% | 8.96% | 0.84x | 1.21x | Nkr-2.63 Million |
| 2022 | -1.73% | -1.64% | 0.71x | 1.49x | Nkr-32.04 Million |
| 2023 | 14.13% | 10.47% | 1.08x | 1.25x | Nkr13.32 Million |
| 2024 | 20.27% | 14.62% | 1.11x | 1.24x | Nkr31.80 Million |
| 2025 | 22.73% | 16.53% | 1.03x | 1.34x | Nkr41.87 Million |
Industry Comparison
This section compares Vistin Pharma ASA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $357,360,000
- Average return on equity (ROE) among peers: 0.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vistin Pharma ASA (VISTN) | Nkr350.31 Million | 6.92% | 0.29x | $87.26 Million |
| Photocure (PHO) | $357.36 Million | 0.00% | 0.13x | $144.74 Million |
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is… Read more